Dexamethasone implant in diabetic macular edema in real-life situations

• Published in: Eye (London) 2016-03, Vol.30 (3), p.426-430
• Main Authors: Chhablani, J, Bansal, P, Veritti, D, Sambhana, S, Sarao, V, Pichi, F, Carrai, P, Massaro, D, Lembo, A, Mansour, A M, Banker, A, Gupta, S R, Hamam, R, Lanzetta, P
• Format: Article
• Language: English
• Subjects: 692/699/3161/3164; 692/699/3161/3175; Aged; Clinical Study; Dexamethasone - administration & dosage; Diabetic Retinopathy - diagnosis; Diabetic Retinopathy - drug therapy; Diabetic Retinopathy - physiopathology; Drug Implants; Female; Fluorescein Angiography; Follow-Up Studies; Glucocorticoids - administration & dosage; Humans; Intraocular Pressure; Intravitreal Injections; Laboratory Medicine; Macular Edema - diagnosis; Macular Edema - drug therapy; Macular Edema - physiopathology; Male; Medicine; Medicine & Public Health; Middle Aged; Ophthalmology; Pharmaceutical Sciences/Technology; Retrospective Studies; Surgery; Surgical Oncology; Tomography, Optical Coherence; Visual Acuity - drug effects
• ISSN: 0950-222X; 1476-5454
• DOI: 10.1038/eye.2015.246

Purpose To report outcome of eyes with recalcitrant and naive eyes with diabetic macular edema (DME) treated with intravitreal dexamethasone implants (Ozurdex) injection. Methods Retrospective multicenter data analysis of eyes with DME treated with Ozurdex implant and with minimum follow-up of at least one year after the first implant. Data collected included demographic details, history of presenting illness, past treatment history, clinical examination details including visual acuity at presentation, and follow-up with imaging and treatment details. Paired sample t -test was used to measure mean differences between pre- and post-implant values obtained at baseline and last follow-up. Results A total of 79 eyes (62 subjects) were included. Sixty-four eyes had been previously treated; 15 eyes were naive. Among the previously treated eyes, mean interval between first Ozurdex injection and any previous treatment was 7.69±8.2 months. In naive eyes, the visual acuity improved from baseline 0.58±0.25 to 0.44±0.33 logMAR at last follow-up ( P =0.05). In eyes that had been previously treated, the improvement was from 0.65±0.34 at baseline to 0.48±0.35 logMAR ( P =0.01). Mean treatment-free interval was 6.5±4.5 months. Nine eyes were steroid responder with controlled intraocular pressure (IOP), none showed any spike in IOP during the follow-up period. Conclusions Ozurdex implant could be a good alternative for recalcitrant as well as naive eyes with DME. The visual gain after initial implant injection was fairly maintained, with additional treatment usually after 6 months in naive eyes. Ozurdex appeared safe even in steroid responders with good control of IOP with antiglaucoma medications.